Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel P Cahill

Showing results (91-100 of 196) with videos related to

Pageof 20
Sort By:
Journal of Neuro-Oncology|November 21, 2014
Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastomaJennie W Taylor, Jorg Dietrich, Elizabeth R Gerstner, et al.
Neuro-Oncology|December 6, 2013
IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resectionJason Beiko, Dima Suki, Kenneth R Hess, et al.
Acta Neuropathologica|February 22, 2015
IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomasAdriana Olar, Khalida M Wani, Kristin D Alfaro-Munoz, et al.
Science (New York, N.Y.)|June 14, 2014
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastomaAnoop P Patel, Itay Tirosh, John J Trombetta, et al.
Neuro-Oncology|June 8, 2019
Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastasesFranziska Maria Ippen, Julia Katharina Grosch, Megha Subramanian, et al.
International Journal of Radiation Oncology, Biology, Physics|August 18, 2012
Predictors of survival in contemporary practice after initial radiosurgery for brain metastasesAnna Likhacheva, Chelsea C Pinnix, Neil R Parikh, et al.
Science (New York, N.Y.)|August 6, 2011
Mutations in CIC and FUBP1 contribute to human oligodendrogliomaChetan Bettegowda, Nishant Agrawal, Yuchen Jiao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2019
The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in <i>PIK3CA</i>-Mutant Breast Cancer Brain MetastasesFranziska M Ippen, Christopher A Alvarez-Breckenridge, Benjamin M Kuter, et al.
Journal of Neurosurgery|January 26, 2024
Genetic characterization and mutational profiling of foramen magnum meningiomas: a multi-institutional studyLingyang Hua, Majd Alkhatib, Shingo Fujio, et al.
Medrxiv : the Preprint Server for Health Sciences|September 2, 2025
IDH1-dependent m6A methylation defines transcriptomic heterogeneity in gliomaSyeda Maheen Batool, Hanna Lee, Koushik Muralidharan, et al.
Pageof 20

Showing results (91-100 of 196) with videos related to

Sort By:
Pageof 20
Journal of Neuro-Oncology|November 21, 2014
Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastomaJennie W Taylor, Jorg Dietrich, Elizabeth R Gerstner, et al.
Neuro-Oncology|December 6, 2013
IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resectionJason Beiko, Dima Suki, Kenneth R Hess, et al.
Acta Neuropathologica|February 22, 2015
IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomasAdriana Olar, Khalida M Wani, Kristin D Alfaro-Munoz, et al.
Science (New York, N.Y.)|June 14, 2014
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastomaAnoop P Patel, Itay Tirosh, John J Trombetta, et al.
Neuro-Oncology|June 8, 2019
Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastasesFranziska Maria Ippen, Julia Katharina Grosch, Megha Subramanian, et al.
International Journal of Radiation Oncology, Biology, Physics|August 18, 2012
Predictors of survival in contemporary practice after initial radiosurgery for brain metastasesAnna Likhacheva, Chelsea C Pinnix, Neil R Parikh, et al.
Science (New York, N.Y.)|August 6, 2011
Mutations in CIC and FUBP1 contribute to human oligodendrogliomaChetan Bettegowda, Nishant Agrawal, Yuchen Jiao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2019
The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in <i>PIK3CA</i>-Mutant Breast Cancer Brain MetastasesFranziska M Ippen, Christopher A Alvarez-Breckenridge, Benjamin M Kuter, et al.
Journal of Neurosurgery|January 26, 2024
Genetic characterization and mutational profiling of foramen magnum meningiomas: a multi-institutional studyLingyang Hua, Majd Alkhatib, Shingo Fujio, et al.
Medrxiv : the Preprint Server for Health Sciences|September 2, 2025
IDH1-dependent m6A methylation defines transcriptomic heterogeneity in gliomaSyeda Maheen Batool, Hanna Lee, Koushik Muralidharan, et al.
Pageof 20